Please assess the completion status of the following clinical trial:

Trial Title: Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Germline BRCA 1/2 Mutation Positive~* Women and men at least 18 years of age or older.~* Histologically confirmed invasive adenocarcinoma of the breast~* HER2 negative breast cancer as defined by ASCO-CAP criteria~* Tumor greater than or equal toT1, N0-3~* No evidence of distant metastasis~* Adequate bone marrow, hepatic, and renal function~* ECOG performance status 0 or 1~Exclusion Criteria:~* Any other previous antitumor therapies for the current cancer event. Treatment for ductal carcinoma in situ (DCIS) is allowed; ie, surgery, hormonal therapy and radiation.~* Evidence of distant metastasis apparent prior to randomization~* Patients with inflammatory breast carcinoma~* Malignancy within the last 3 years, except: Stage 1 melanoma which does not require any further treatment after adequate surgical excision; adequately treated non melanoma skin cancer; Curatively treated in situ cancer of the cervix; Stage 1, Grade 1 endometrial carcinoma; or Adequately treated contralateral breast carcinoma which has been disease free for a year; Other solid tumors including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for 5 years.~* Previous or concomitant systemic anti cancer therapies used for the treatment of cancer in the last 3 years.~* Prior treatment with a PARP inhibitor in any disease setting~* Concomitant use of Strong P gp inhibitors or inducers or BCRP inhibitors~* Patients who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol~* Major surgery within 14 days prior to study entry~* Known history of cardiac disease, for example : Myocardial infarction or symptomatic cardiac ischemia within 24 weeks before screening; Congestive heart failure New York Heart Association Class III or IV; History of clinically significant ventricular arrhythmias within one year prior to randomization; History of Mobitz II second degree or third degree heart block, uncontrolled hypertension.~* Active clinically significant infection~* Clinically significant bleeding diathesis or coagulopathy~* Non healing wound, ulcer or bone fracture~* Known hypersensitivity to any of the components of talazoparib~* Patients with myelodysplastic syndrome/acute myeloid leukemia~* Patients with uncontrolled seizures.~* Any evidence of other disease or any concomitant medical or psychiatric problems which in the opinion of the Investigator would prevent completion of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TALAZOPARIB (Type: EXPERIMENTAL): SINGLE ARM, NON-RANDOMIZED

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy